Related Experiment Video
Updated: Apr 30, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
Mutant IDH1 inhibits PI3K/Akt signaling in human glioma
Peter Birner1, Stefan Pusch, Christo Christov
1Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria.
Background:
Recently, isocitrate dehydrogenase 1 (IDH1) was identified as a major participant in glioma pathogenesis. At present, the enzymatic activity of the protein has been the main topic in investigating its physiological function, but its signaling pathway allocation was unsuccessful. Interestingly, proteins regulated by phosphoinositide 3-kinase (PI3K)/Akt signaling, are among the top downregulated genes in gliomas associated with high percentage of IDH1 and IDH2 mutations. The aim of this study was to investigate a hypothetical relation between IDH1 and PI3K signaling.
Methods:
The presence of mutant IDH1 and markers for active PI3K/Akt signaling, present as phosphorylated Akt and podoplanin (PDPN), were investigated in a discovery cohort of 354 patients with glioma. In vitro experiments were used to confirm functional links.
Results:
This study shows an inverse correlation between mutant IDH1 and markers for active PI3K/Akt signaling. In support of a functional link between these molecules, in vitro expression of mutant IDH1 inhibited Akt phosphorylation in a 2-hydroxyglutarate-dependent manner.
Conclusions:
This study provides patient tumor and in vitro evidence suggesting that mutant IDH1 inhibits PI3K/Akt signaling.
Insights
Mutant isocitrate dehydrogenase 1 (IDH1) inhibits phosphoinositide 3-kinase (PI3K)/Akt signaling in gliomas. This study found an inverse correlation between mutant IDH1 and active PI3K/Akt signaling markers.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Signaling Pathways
Background:
- Isocitrate dehydrogenase 1 (IDH1) is crucial in glioma development.
- The role of IDH1 in signaling pathways remains unclear.
- Genes regulated by phosphoinositide 3-kinase (PI3K)/Akt signaling are downregulated in IDH-mutated gliomas.
Purpose of the Study:
- To investigate a potential link between IDH1 and PI3K/Akt signaling.
- To determine if mutant IDH1 affects PI3K/Akt pathway activity.
Main Methods:
- Examined mutant IDH1 and PI3K/Akt signaling markers (phosphorylated Akt, podoplanin) in 354 glioma patients.
- Conducted in vitro experiments to confirm functional relationships.
Main Results:
- An inverse correlation was observed between mutant IDH1 and active PI3K/Akt signaling markers.
- In vitro, mutant IDH1 expression inhibited Akt phosphorylation in a 2-hydroxyglutarate-dependent manner.
Conclusions:
- Mutant IDH1 appears to inhibit PI3K/Akt signaling.
- Evidence from patient tumors and in vitro studies supports this inhibitory role.
More Related Videos
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
The JAK-STAT Signaling Pathway
Hedgehog Signaling Pathway

